Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

(OP:LOBEF)

0.0296 -0.0016 (-5.13%)
Streaming Delayed Price Updated: 12:20 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LOBEF

< Previous 1 2 Next >
Lobe Sciences Completes Debt Settlement to Improve Balance Sheet
Via ACCESS Newswire
Lobe Sciences Improves Balance Sheet
Via ACCESS Newswire
Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025
Via ACCESS Newswire
Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors
Via ACCESS Newswire
Lobe Sciences Announces the Closing of the Previously Announced Private Placement
Via ACCESS Newswire
Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory
Via ACCESS Newswire
Lobe Sciences Ltd. Announces Debt Settlement
Via ACCESS Newswire
Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease
Via ACCESS Newswire
Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals
Via ACCESS Newswire
Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth
Via ACCESS Newswire
Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)
Via ACCESS Newswire
Lobe Sciences Provides Corporate Update
Via ACCESS Newswire
Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™
From Lobe Sciences, Ltd.
Via Business Wire
Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
From Lobe Sciences, Ltd.
Via Business Wire
Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
From Lobe Sciences Ltd
Via Business Wire
Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
From Lobe Sciences Ltd
Via Business Wire
Lobe Sciences Announces Update
From Lobe Sciences Ltd.
Via Business Wire
Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors
From Lobe Sciences Ltd.
Via Business Wire
Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders
From Lobe Sciences Ltd.
Via Business Wire
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
Via Benzinga
Lobe Sciences Provides Company Review of 2023
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Provides Update on L-130 Clinical Program
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company
From Lobe Sciences Ltd.
Via Business Wire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical... 
Via Benzinga
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
From Lobe Sciences Ltd.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.